A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)

NATerminatedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Hemophilia A
Interventions
PROCEDURE

Biospecimen Collection

Biospecimen Sample Collection

Trial Locations (18)

1090

Medical University of Vienna, Vienna

2050

Royal Prince Alfred Hospital, Camperdown

6150

Haemophilia and Haemostasis Centre Level 1 Cancer Centre South Metropolitan Health Service Fiona Stanley Hospital, Murdoch

11211

King Faisal Specialist Hospital & Research Center, Riyadh

11393

Sheikh Shakhbout Medical City, Abu Dhabi

12372

King Saud University Medical City King Saud University, Riyadh

27310

Gaziantep University Medical Faculty Sahinbey Educational Research Hospital, Gaziantep

34098

Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Istanbul

35040

Ege University Medical Faculty, Izmir

55270

Ondokuz Mayis Univ. Med. Fac., Samsun

M5504FKD

Instituto Hematologia Arbesu, Godoy Cruz

W3410 FND

Hospital Ramon Jose Vidal, Corrientes

Unknown

Medico Hematologo, Mendoza

S2000 CFK

Instituto de Hematologia y Medicina Clinica Dr. RUben Davoli, Rosario

205 02

Skane University Hospital, Malmo

SE-171 76

ME Centrum för kliniska cancerstudier - House H3, Solna

01130

Acibadem Adana Hospital, Adana

06100

Hacettepe University, Ankara

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY